{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-065597","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.708274+00:00","generated_at":"2026-06-11T20:06:24.328092+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ImmuCell Q2 sales down 9% to $3.5M; net loss widens to $1.4M from $684K","bullets":["Product sales $3.5M in Q2 2023 vs $3.9M in Q2 2022 (-9%); gross margin fell to 30% from 44%.","Net loss $(1.4M) or $(0.18)/share vs $(0.684M) or $(0.09)/share in prior-year quarter.","Six-month net loss widened to $(3.7M) from $(171K); EBITDA turned negative $(2.2M) vs positive $1.2M.","Cash dropped to $1.5M from $5.8M at Dec 31, 2022; raised $3M debt facility with 7-year amortization.","CEO cites production contamination remediation; goal to reach ~$6M quarterly output (80% of $30M capacity)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-065597","json":"https://secwatch.observer/filing/0001213900-23-065597.json","markdown":"https://secwatch.observer/filing/0001213900-23-065597.md","text":"https://secwatch.observer/filing/0001213900-23-065597.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000121390023065597/0001213900-23-065597-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000121390023065597/ea183184-8k_immucell.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T20:06:24.328092+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d18357da6277e21ea381b669431e753bd7a4dbd6","claim":"IMMUCELL CORP /DE/ reported the quarter ended June 30, 2023 results: revenue $3.5 million, net income ($1.4) million, EPS ($0.18) per basic share.","evidence_excerpt":"review shortly, which is a critical milestone in our efforts to commercialize this product.” 1 of 6 Certain Financial Results: ● Product sales decreased by 9%, or $329,000, to $3.5 million during the three-month period ended June 30, 2023 compared to $3.9 million during the three-month period ended June 30, 2022. ● Product sales decreased by 29%, or $2.9 million,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000121390023065597/0001213900-23-065597-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$3.5 million"},{"label":"Net income","value":"($1.4) million"},{"label":"EPS","value":"($0.18) per basic share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f172206bb73ba195a6608ffd03023963b0cc7d9b","claim":"IMMUCELL CORP /DE/ reported the six-month period ended June 30, 2023 results: revenue $7.0 million, net income ($3.7) million, EPS ($0.48) per basic share.","evidence_excerpt":"the three-month period ended June 30, 2023 compared to $3.9 million during the three-month period ended June 30, 2022. ● Product sales decreased by 29%, or $2.9 million, to $7.0 million during the six-month period ended June 30, 2023 compared to $9.9 million during the six-month period ended June 30, 2022. ● Product sales decreased by 23%, or $4.8 million, to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000121390023065597/0001213900-23-065597-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six-month period ended June 30, 2023"},{"label":"Revenue","value":"$7.0 million"},{"label":"Net income","value":"($3.7) million"},{"label":"EPS","value":"($0.48) per basic share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f8c06176509fb6e248a2dfc9d9fb622fb3c8926e","claim":"IMMUCELL CORP /DE/ reported the trailing twelve-month period ended June 30, 2023 results: revenue $15.7 million.","evidence_excerpt":"Product sales decreased by 23%, or $4.8 million, to $15.7 million during the trailing twelve-month period ended June 30, 2023 compared to $20.5 million during the trailing twelve-month period ended June 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000121390023065597/0001213900-23-065597-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the trailing twelve-month period ended June 30, 2023"},{"label":"Revenue","value":"$15.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}